Real-World Study on Efficacy and Influencing Factors of Immunotherapy for Pan-Cancer Lymph Node Metastases.

Inclusion Criteria: \- Histopathologically or cytologically confirmed malignant solid tumors (including non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, bladder cancer, breast cancer, esophageal cancer, liver cancer, pancreatic cancer, melanoma, etc.) Confirmed regional or distant lymph node metastasis by imaging (enhanced CT/MRI/PET-CT) or pathological examination Received at least 1 cycle of ICI therapy (monotherapy or combined therapy) with clear treatment initiation time and regimen records Complete clinical diagnosis, treatment, efficacy evaluation and follow-up records, with available baseline and post-immunotherapy imaging for T/N stage assessment Evaluable tumor lesions according to the RECIST 1.1 criteria Clear β-blocker use records in medical records Aged ≥18 years, regardless of gende Exclusion Criteria: * Less than 1 cycle of ICI therapy, unevaluable efficacy, or missing medication time/regimen information Incomplete clinical records with missing key data for analysis Complicated with other synchronous or metachronous malignant tumors Received other anti-tumor immunotherapy before ICI therapy (e.g., adoptive cell therapy, tumor vaccine) Unclear diagnosis of lymph node metastasis or unlocatable/evaluable lymph node metastatic lesions Pregnant women, or patients whose data cannot be desensitized or meet ethical/data compliance requirements Imaging cannot distinguish the changes of primary tumors and lymph node lesions